Listed

Incannex Healthcare Inc.

IXHLNasdaqCIK 1873875HealthcareFiscal year ends Jun 30

Latest reported revenue, Q4 FY2025$0Revenue, Q4 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Jun 30, 2025, from the 10-K filed Sep 25, 2026.

Latest quarter: Q4 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flow$3.4mFree cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Capital expenditure: −$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$0Operating margin not reported
Diluted EPS−$0.35, Q3 FY2026
Free cash flow$3.4m, Q4 FY2026
Incannex Healthcare Inc., key figures for the last eight quarters
Line itemUnitQ1 FY20252024-09-30Q2 FY20252024-12-31Q3 FY20252025-03-31Q4 FY20252025-06-30Q1 FY20262025-09-30Q2 FY20262025-12-31Q3 FY20262026-03-31Q4 FY20262026-06-30Shape over the periods
Revenue$k74.0Revenue, Q1 FY2025, three months to 2024-09-30$74.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-14, accession 0001213900-24-098421.Report this figure12.0Revenue, Q2 FY2025, three months to 2024-12-31$12.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-02-14, accession 0001213900-25-013783.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-15, accession 0001213900-25-043682. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%(8451.4%)Operating margin, Q1 FY2025, three months to 2024-09-30. operating income / revenueOperating income: −$6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001213900-25-110299.Revenue: $74.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-14, accession 0001213900-24-098421.Report this figure(41700.0%)Operating margin, Q2 FY2025, three months to 2024-12-31. operating income / revenueOperating income: −$5.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-13, accession 0001213900-26-015867.Revenue: $12.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-02-14, accession 0001213900-25-013783.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%(7324.3%)Net margin, Q1 FY2025, three months to 2024-09-30. net income / revenueNet income: −$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001213900-26-057227.Revenue: $74.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-14, accession 0001213900-24-098421.Report this figure(49116.7%)Net margin, Q2 FY2025, three months to 2024-12-31. net income / revenueNet income: −$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001213900-26-057227.Revenue: $12.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-02-14, accession 0001213900-25-013783.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(0.29)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110299.Report this figure(0.33)Diluted EPS, Q2 FY2025, three months to 2024-12-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-13, accession 0001213900-26-015867.Report this figure(6.19)Diluted EPS, Q3 FY2025, three months to 2025-03-31−$6.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001213900-26-057227.Report this figurenot reported (Diluted EPS not reported)(0.02)Diluted EPS, Q1 FY2026, three months to 2025-09-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001213900-25-110299.Report this figure(0.02)Diluted EPS, Q2 FY2026, three months to 2025-12-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-13, accession 0001213900-26-015867.Report this figure(0.35)Diluted EPS, Q3 FY2026, three months to 2026-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001213900-26-057227.Report this figurenot reported (Diluted EPS not reported)
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(3,159)Free cash flow, Q3 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001213900-26-057227. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001213900-26-057227. Derived: 9-month figure less the 6-month figure.Report this figure(1,482)Free cash flow, Q4 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Report this figure(9,165)Free cash flow, Q1 FY2026, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001213900-25-110299.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001213900-25-110299.Report this figure(4,626)Free cash flow, Q2 FY2026, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-13, accession 0001213900-26-015867. Derived: 6-month figure less the 3-month figure.Capital expenditure: $4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-13, accession 0001213900-26-015867. Derived: 6-month figure less the 3-month figure.Report this figure(2,461)Free cash flow, Q3 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001213900-26-057227. Derived: 9-month figure less the 6-month figure.Capital expenditure: $5.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001213900-26-057227. Derived: 9-month figure less the 6-month figure.Report this figure3,373Free cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Capital expenditure: −$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-25, accession 0001628280-26-063506. Derived: 12-month figure less the 9-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$0Operating margin not reported
Diluted EPS−$1.66, FY2026
Free cash flow−$12.9m, FY2026
Incannex Healthcare Inc., key figures for the last five fiscal years
Line itemUnitFY20222022-06-30FY20232023-06-30FY20242024-06-30FY20252025-06-30FY20262026-06-30Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)0.0Revenue, FY2024, twelve months to 2024-06-30$12.0k. XBRL concept us-gaap:Revenues. 10-K filed 2024-09-30, accession 0001213900-24-082937.Report this figure0.1Revenue, FY2025, twelve months to 2025-06-30$86.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figure0.0Revenue, FY2026, twelve months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Operating income and Revenue not reported)not reported (Revenue not reported)(250341.7%)Operating margin, FY2024, twelve months to 2024-06-30. operating income / revenueOperating income: −$30.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-09-29, accession 0001213900-25-092837.Revenue: $12.0k. XBRL concept us-gaap:Revenues. 10-K filed 2024-09-30, accession 0001213900-24-082937.Report this figure(27661.6%)Operating margin, FY2025, twelve months to 2025-06-30. operating income / revenueOperating income: −$23.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-25, accession 0001628280-26-063506.Revenue: $86.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figurenot reported (Revenue of zero not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)(153825.0%)Net margin, FY2024, twelve months to 2024-06-30. net income / revenueNet income: −$18.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-09-29, accession 0001213900-25-092837.Revenue: $12.0k. XBRL concept us-gaap:Revenues. 10-K filed 2024-09-30, accession 0001213900-24-082937.Report this figure(54517.4%)Net margin, FY2025, twelve months to 2025-06-30. net income / revenueNet income: −$46.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-25, accession 0001628280-26-063506.Revenue: $86.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figurenot reported (Revenue of zero not reported)
Diluted EPS$ per share(1.25)Diluted EPS, FY2022, twelve months to 2022-06-30−$1.25 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2023-10-31, accession 0001213900-23-081650.Report this figure(3.32)Diluted EPS, FY2023, twelve months to 2023-06-30−$3.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-09-30, accession 0001213900-24-082937.Report this figure(1.15)Diluted EPS, FY2024, twelve months to 2024-06-30−$1.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-09-29, accession 0001213900-25-092837.Report this figure(40.82)Diluted EPS, FY2025, twelve months to 2025-06-30−$40.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figure(1.66)Diluted EPS, FY2026, twelve months to 2026-06-30−$1.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)(11.1)Free cash flow, FY2023, twelve months to 2023-06-30. operating cash flow − capital expenditureOperating cash flow: −$10.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-09-30, accession 0001213900-24-082937.Capital expenditure: $316.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-09-30, accession 0001213900-24-082937.Report this figure(16.1)Free cash flow, FY2024, twelve months to 2024-06-30. operating cash flow − capital expenditureOperating cash flow: −$15.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-09-29, accession 0001213900-25-092837.Capital expenditure: $277.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-09-29, accession 0001213900-25-092837.Report this figure(12.5)Free cash flow, FY2025, twelve months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$12.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-25, accession 0001628280-26-063506.Capital expenditure: $8.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figure(12.9)Free cash flow, FY2026, twelve months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$12.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-25, accession 0001628280-26-063506.Capital expenditure: $10.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-25, accession 0001628280-26-063506.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Incannex Healthcare Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
LPL Financial LLC2026-06-30$557.1k148,178Added+77,000
MILLENNIUM MANAGEMENT LLC2026-06-30$358.1k95,252New+95,252
JANE STREET GROUP, LLC2026-06-30$294.0k78,195New+78,195
AdvisorShares Investments LLC2026-06-30$228.9k60,868Added+36,365
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$108.2k28,771New+28,771
SUSQUEHANNA INTERNATIONAL GROUP, LLP2026-06-30$62.0k16,500PutNew+16,500
COMMONWEALTH EQUITY SERVICES, LLC2026-06-30$52.8k14,029Added+1,917
CITADEL ADVISORS LLC2026-06-30$38.9k10,349New+10,349
OSAIC HOLDINGS, INC.2026-06-30$24.0k6,376Unchanged
UBS Group AG2026-06-30$13.6k3,610Reduced−36,759

Recent filings

All 263 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Incannex Healthcare Inc., recent filings
FiledFormWhat it isAccession number
2026-09-2508:41 ET10-KAnnual reportPeriod 2026-06-300001628280-26-063506
2026-09-0907:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-098213
2026-08-2507:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-093244
2026-08-1107:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-087493
2026-07-2307:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-080622
2026-06-2507:31 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-071745
2026-06-1007:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-067081
2026-06-0907:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-066526
2026-05-1509:29 ET10-QQuarterly reportPeriod 2026-03-310001213900-26-057227
2026-05-1407:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-056227

Latest annual report

Form 10-K for the fiscal year ended Jun 30, 2026Filed Sep 25, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1873875
Tickers
IXHL
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Jun 30
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Former names
Incannex Healthcare Ltd (to 2023-11-29)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.